Our business model

We operate in a competitive, highly-regulated industry. Our
diversified business model allows us to respond to the many
opportunities and risks we face, while delivering value for our
all our stakeholders.

Our activities are diversified across our business segments and markets and are aligned with our purpose to make high-quality medicines accessible to the people who need them.

Develop and innovate

We are developing a broad and differentiated portfolio of generic, branded generic and in-licensed patented products through internal R&D, co-development partnerships, licensing agreements and acquisitions.

Manufacture and maintain quality

We are committed to maintaining high-quality standards in all of our manufacturing facilities. We have 31 plants across the Group that supply our global markets with a broad range of injectable and non-injectable products, including 11 US FDA-inspected plants and 11 EMA-inspected plants.

Manufacturing plants
US FDA-inspected plants
EMA-inspected plants

Markets across geographies

We distribute our products in our markets through experienced sales and marketing teams. In the MENA region, around 2,000 representatives market our brands to doctors and pharmacists, while our sales teams in the US and Europe sell to a broad range of customers, including the leading wholesalers, pharmacy chains, governments and hospital purchasing organisations.

sales representatives market our products across MENA

We provide our patients with access to our high-quality medicines
employee engagement score

By focusing on the engagement and development of our people, we provide long and rewarding careers for our talented and diverse workforce.
Total shareholder return over the last ten years

We have a long history of creating value for our shareholders.
- Patron of the Prince's Trust

- Member of the United Nations Global
Compact and FTSE4Good

By acting responsibly and with integrity, we are benefiting the communities in which we operate.